

AMENDMENTS

In the Claims:

Please cancel claims 1-53 and 120-129 as drawn to non-elected subject matter. Please amend the claims as follows:

1. – 53. (Cancelled)

54. (Currently amended) A method of treating a subject having cancer, comprising administering to said individual a therapeutically effective amount of a composition comprising N-(4-hydroxyphenyl) retamide, or a derivative thereof, encapsulated in a lipid material, wherein said lipid material comprises dimyristoyl phosphatidylcholine (DMPC) and one or more of soybean oil (SO) and water.
55. (Original) The method of claim 54, wherein said dimyristoyl phosphatidylcholine and soybean oil comprise a ratio of greater than 80:20.
56. (Original) The method of claim 54, wherein said composition is comprised in a pharmaceutically acceptable aqueous medium.
57. (Original) The method of claim 54, wherein said method further comprises administering at least one additional therapeutic agent to said individual.
58. (Currently Amended) The method of claim ~~57~~58, wherein said agent is comprised in said composition.
59. (Original) The method of claim 57, wherein said additional therapeutic agent comprises at least one anticancer agent.
60. (Original) The method of claim 59, wherein the anticancer agent is chemotherapy agent, a radiotherapy agent, an immune therapy agent, a genetic therapy agent, a hormonal therapy agent, a biological agent, an additional retinoid or a retinoid derivative.

61. (Withdrawn) A method for increasing growth inhibitory effects of fenretinide on a cell comprising providing to a cell, in combination with fenretinide, one or more agents that increases the level of nitric oxide (NO) in said cell.
62. (Withdrawn) The method of claim 61, wherein said cell is a tumor cell.
63. (Withdrawn) The method of claim 62, wherein said tumor cell is a breast cancer cell.
64. (Withdrawn) The method of claim 63, wherein the breast cancer cell is an estrogen receptor (ER)-positive cell.
65. (Withdrawn) The method of claim 63, wherein the breast cancer cell is an estrogen receptor (ER)-negative cell.
66. (Withdrawn) The method of claim 61, wherein fenretinide is provided before the one or more agents.
67. (Withdrawn) The method of claim 61, wherein fenretinide is provided at the same time as the one or more agents.
68. (Withdrawn) The method of claim 61, wherein fenretinide is provided after the one or more agents.
69. (Withdrawn) The method of claim 61, wherein fenretinide is provided more than once.
70. (Withdrawn) The method of claim 69, wherein fenretinide is provided daily for three months with monthly three-day interruptions.
71. (Withdrawn) The method of claim 61, wherein said agent is provided more than once.
72. (Withdrawn) The method of claim 61, wherein said agent is a nucleic acid.
73. (Withdrawn) The method of claim 72, wherein said nucleic acid is an expression construct encoding iNOS, interferon- γ or herceptin.

74. (Withdrawn) The method of claim 61, wherein said agent is a protein.
75. (Withdrawn) The method of claim 74, wherein said protein is iNOS, interferon- γ or herceptin.
76. (Withdrawn) The method of claim 61, wherein said agent is a chemopharmaceutical.
77. (Withdrawn) The method of claim 76, wherein said agent is cyclosporin A.
78. (Withdrawn) The method of claim 62, wherein said cell tumor cell is a patient.
79. (Withdrawn) The method of claim 78, wherein said cell tumor cell is part of a tumor mass in said patient.
80. (Withdrawn) The method claim 78, wherein providing comprises direct administration to said tumor cell.
81. (Withdrawn) The method of claim 61, further comprising providing to said cell an additional anti-cancer therapy.
82. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is radiation.
83. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is a distinct chemotherapy.
84. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is a distinct gene therapy.
85. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is immunotherapy.
86. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is hormonal therapy.

87. (Withdrawn) The method of claim 61, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration of 0.1 μM .
88. (Withdrawn) The method of claim 61, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration of 0.5 μM .
89. (Withdrawn) The method of claim 61, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration of 1.0 μM .
90. (Withdrawn) The method of claim 61, wherein said cell is killed.
91. (Withdrawn) A method for treating cancer in a subject comprising providing to said subject, in combination, fenretinide and one or more agents that increases the level of nitric oxide (NO) in cancer cells in said subject.
92. (Withdrawn) The method of claim 91, wherein said cancer is a breast cancer.
93. (Withdrawn) The method of claim 92, wherein cells of said breast cancer are estrogen receptor (ER)-positive.
94. (Withdrawn) The method of claim 92, wherein cells of said breast cancer are estrogen receptor (ER)-negative.
95. (Withdrawn) The method of claim 91, wherein fenretinide is provided before the one or more agents.
96. (Withdrawn) The method of claim 91, wherein fenretinide is provided at the same time as the one or more agents.
97. (Withdrawn) The method of claim 91, wherein fenretinide is provided after the one or more agents.
98. (Withdrawn) The method of claim 91, wherein fenretinide is provided more than once.
99. (Withdrawn) The method of claim 98, wherein fenretinide is provided daily for three months with monthly three-day interruptions.

100. (Withdrawn) The method of claim 91, wherein said agent is provided more than once.
101. (Withdrawn) The method of claim 91, wherein said agent is a nucleic acid.
102. (Withdrawn) The method of claim 101, wherein said nucleic acid is an expression construct encoding iNOS, interferon- γ or herceptin.
103. (Withdrawn) The method of claim 91, wherein said agent is a protein.
104. (Withdrawn) The method of claim 103, wherein said protein is iNOS, interferon- γ or herceptin.
105. (Withdrawn) The method of claim 91, wherein said agent is a chemopharmaceutical.
106. (Withdrawn) The method of claim 105, wherein said agent is cyclosporin A.
107. (Withdrawn) The method claim 91, wherein providing comprises direct administration to said tumor cell.
108. (Withdrawn) The method of claim 91, further comprising providing to said cell an additional anti-cancer therapy.
109. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is radiation.
110. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is a distinct chemotherapy.
111. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is a distinct gene therapy.
112. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is immunotherapy.
113. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is hormonal therapy.

114. (Withdrawn) The method of claim 91, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration in cancer cells of 0.1 μM .
115. (Withdrawn) The method of claim 91, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration in cancer cells of 0.5 μM .
116. (Withdrawn) The method of claim 91, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration in cancer cells of 1.0 μM .
117. (Withdrawn) The method of claim 91, wherein fenretinide is provided at 10 mg/day.
118. (Withdrawn) The method of claim 91, wherein fenretinide is provided at 100 mg/day.
119. (Withdrawn) The method of claim 91, wherein fenretinide is provided at 200 mg/day.
120. – 129. (Cancelled)
130. (Withdrawn) A method for inhibiting metastasis in a subject having cancer comprising providing to said subject, in combination, fenretinide and one or more agents that increases the level of nitric oxide (NO) in cancer cells in said subject.
131. (New) The method of claim 54, wherein the composition is administered parenterally to the individual.
132. (New) The method of claim 54, wherein the composition is administered orally to the individual.
133. (New) The method of claim 54, wherein the lipid material comprises DMPC and SO.
134. (New) The method of claim 133, comprising a ratio of 4-HPR, or derivative thereof, to DMPC/SO of from 1:5 to 1:15.
135. (New) The method of claim 134, wherein the 4-HPR, or derivative thereof, to DMPC/SO ratio is about 1:5 (w/w).

136. (New) The method of claim 134, wherein the 4-HPR, or derivative thereof, to DMPC/SO ratio is about 1:10 (w/w).
137. (New) The method of claim 134, wherein the 4-HPR, or derivative thereof, to DMPC/SO ratio is about 1:15 (w/w).
138. (New) The method of claim 54, wherein the lipid material comprises DMPC and water.
139. (New) The method of claim 138, wherein the composition comprises from 1 to 10% water.
140. (New) The method of claim 139, wherein the composition comprises about 10% water.
141. (New) The method of claim 54, wherein the lipid material comprises DMPC, SO and water.